Drugmaker Moderna said Monday it has begun a 30,000-patient, third-stage clinical trial for its COVID-19 vaccine candidate — a day after receiving an additional $472 million from the U. S. government.
July 27 (UPI) — Drugmaker Moderna said Monday it has begun a 30,000-patient, third-stage clinical trial for its COVID-19 vaccine candidate — a day after receiving an additional $472 million from the U. S. government.
Called the COVE, or Coronavirus Efficacy, study, the trial is being performed at 100 clinical research sites in collaboration with the National Institute of Allergy and Infectious Diseases and the U. S. Biomedical Advanced Research and Development Authority, or BARDA.
Moderna said it has begun dosing human participants.
